Kintara Therapeutics, Inc. (KTRA) Stock Analysis
DELISTED 2024
What happened to Kintara Therapeutics, Inc. (KTRA) stock?
Kintara Therapeutics, Inc. (KTRA) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kintara Therapeutics, Inc. (KTRA) trades at $0.2154. Kintara Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing anti-cancer treatments. The company is advancing two key compounds, VAL-083 and REM-001, towards commercialization. Market cap: $12.0M, Sector: Healthcare.
Last analyzed: Jun 15, 2026Analyst Coverage for KTRA: KTRA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KTRA against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
KTRA: 2/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Kintara Therapeutics, Inc. (KTRA) Healthcare & Pipeline Overview
Kintara Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative anti-cancer therapies, with a focus on VAL-083 and REM-001, targeting unmet medical needs in oncology.
What Is the Investment Thesis for KTRA?
Kintara Therapeutics, Inc. presents a unique investment thesis centered around its innovative pipeline of anti-cancer therapies. The company's lead candidate, VAL-083, targets drug-resistant solid tumors, addressing a significant unmet need in oncology, particularly for patients with glioblastoma multiforme. The upcoming Phase III trials for both VAL-083 and REM-001 are critical milestones that could unlock substantial value for the company. Additionally, the strategic alliance with Guangxi Wuzhou Pharmaceutical enhances Kintara's market access in China, a rapidly growing market for oncology treatments. However, the company faces risks associated with clinical trial outcomes and the need for ongoing funding, which could impact its financial stability and growth trajectory. Monitoring these developments will be essential for understanding Kintara's future performance.
Based on FMP financials and quantitative analysis
KTRA Key Highlights
Market capitalization of $12.0M, reflecting the company's early-stage status in the biotechnology sector.
- Beta of 0.81, indicating lower volatility compared to the broader market.
- No dividend yield, consistent with typical biotechnology firms focused on reinvestment in R&D.
- Strategic alliance with Guangxi Wuzhou Pharmaceutical to enhance market presence in China.
- Two compounds, VAL-083 and REM-001, advancing towards Phase III trials, indicating progress in the clinical development pipeline.
Who Are KTRA's Competitors?
KTRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NTRA Natera, Inc. | $325.07 | +4.29% | $46.6B | 35 |
| RGEN Repligen Corporation | $180.29 | +2.23% | $10.2B | 81 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KTRA's Key Strengths?
Innovative pipeline with two compounds nearing Phase III trials.
- Strategic partnership with Guangxi Wuzhou Pharmaceutical to access the Chinese market.
- Strong focus on addressing unmet needs in oncology, particularly drug-resistant tumors.
What Are KTRA's Weaknesses?
Limited resources with only one employee, potentially impacting operational capacity.
- Dependence on successful clinical trial outcomes for future funding and growth.
- Current lack of recurring revenue streams, typical for clinical-stage companies.
What Could Drive KTRA Stock Higher?
Phase III trial results for VAL-083 expected in Q4 2026.
- Partnership with Guangxi Wuzhou Pharmaceutical for VAL-083 production and sales in China.
- Potential regulatory submissions for VAL-083 and REM-001 following successful trial outcomes.
What Are the Key Risks for KTRA?
Financial-distress signal — its Altman Z-Score of -6.66 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Dependence on successful clinical trial results for future funding and growth.
- Regulatory hurdles that could delay product approvals and market entry.
- High competition from established biotechnology firms in the oncology space.
What Are the Growth Opportunities for KTRA?
- Growth opportunity 1: Kintara's lead compound, VAL-083, targets drug-resistant solid tumors, a significant market segment projected to grow as more patients seek effective treatments for glioblastoma multiforme and other resistant cancers. The global market for glioblastoma therapies is expected to reach $3 billion by 2027, and successful Phase III trial results could position Kintara as a key player in this lucrative market.
- Growth opportunity 2: The strategic partnership with Guangxi Wuzhou Pharmaceutical opens up the Chinese market for VAL-083, which is experiencing rapid growth in demand for innovative cancer therapies.
- Growth opportunity 3: REM-001, targeting cutaneous metastatic breast cancer, addresses a niche yet critical area of oncology with limited treatment options. As the incidence of metastatic breast cancer continues to rise, the demand for effective therapies is increasing, presenting Kintara with an opportunity to capture market share in this therapeutic area.
- Growth opportunity 4: The ongoing advancements in biotechnology and personalized medicine create a favorable environment for Kintara's innovative therapies. As healthcare providers increasingly seek targeted treatments, Kintara's unique mechanisms of action for VAL-083 and REM-001 may appeal to clinicians and patients alike, enhancing adoption rates and driving revenue growth.
- Growth opportunity 5: Kintara's potential to secure additional partnerships or collaborations with larger pharmaceutical companies could provide access to resources, expertise, and funding necessary to accelerate its clinical development programs. Such collaborations could enhance Kintara's capabilities and market reach, further solidifying its position in the biotechnology landscape.
What Are KTRA's Competitive Advantages?
- Unique mechanisms of action for its lead compounds, providing a competitive edge.
- Strategic partnerships enhancing market access and distribution capabilities.
- Focus on unmet medical needs in oncology, positioning Kintara as a specialized provider.
- Clinical-stage pipeline with potential for high-impact therapies in oncology.
What Does KTRA Do?
Founded in 2009 and headquartered in San Diego, California, Kintara Therapeutics, Inc. operates as a clinical-stage biotechnology firm with a mission to pioneer and commercialize anti-cancer treatments. The company, originally known as DelMar Pharmaceuticals, Inc., rebranded to Kintara Therapeutics in August 2020 to better reflect its focus on innovative cancer therapies. Kintara's pipeline features two promising compounds nearing Phase III trials: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy specifically targeting cutaneous metastatic breast cancer. Kintara has established a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to facilitate the production and sale of VAL-083 in the Chinese market, expanding its geographic reach and potential market impact. As a clinical-stage company, Kintara is currently focused on advancing its clinical trials and securing necessary funding to support its innovative research and development efforts, positioning itself as a key player in the oncology space.
What Products and Services Does KTRA Offer?
- Develop anti-cancer therapies targeting drug-resistant solid tumors.
- Advance clinical-stage compounds through rigorous testing and trials.
- Collaborate with strategic partners to enhance market access and distribution.
- Focus on innovative treatment mechanisms to address unmet medical needs.
- Engage in research and development to expand its oncology pipeline.
- Seek regulatory approvals for its therapies to enter the market.
How Does KTRA Make Money?
- Generate revenue through the commercialization of successful cancer therapies.
- Leverage strategic partnerships for production and sales in key markets.
- Focus on clinical trial outcomes to drive investor interest and funding.
- Utilize research grants and funding to support ongoing development efforts.
What Industry Does KTRA Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in oncology. The global cancer therapeutics market is projected to grow substantially, driven by increasing cancer prevalence and demand for novel therapies. Kintara Therapeutics, with its focus on anti-cancer treatments, is positioned within this dynamic landscape, competing against established players and emerging biotech firms. The industry's growth is fueled by advancements in personalized medicine and targeted therapies, creating opportunities for companies like Kintara to address unmet medical needs in oncology.
Who Are KTRA's Key Customers?
- Oncology patients seeking innovative treatment options.
- Healthcare providers and oncologists looking for effective therapies.
- Pharmaceutical partners interested in collaboration for product development.
- Research institutions focusing on cancer treatment advancements.
Company Profile
Kintara Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jeffrey A. Bacha. KTRA has traded publicly since 2013.
How Kintara Therapeutics, Inc. Is Valued
Kintara Therapeutics, Inc. carries a market capitalization of $12.0M, placing it in the micro-cap category.
Key Financial Metrics
Its free cash flow yield is -18.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Kintara Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.66 places it in the distress zone, a signal of elevated financial risk.
KTRA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Kintara's pipeline, indicating that key stakeholders believe in the company's future prospects.
- Community sentiment has shifted positively with discussions around upcoming clinical trial results, reflecting optimism among investors.
- Increased media coverage on Kintara's innovative therapies has sparked interest, leading to a more engaged investor base.
- Positive developments in regulatory discussions have bolstered the perception of Kintara's potential to bring its therapies to market.
Bear Case
- Concerns over the company's cash runway have surfaced, leading some investors to question its ability to fund operations without additional financing.
- Recent social sentiment shows a divide, with some community members expressing skepticism about the viability of Kintara's drug candidates.
- Market perception has been affected by broader industry challenges, including increased competition in the biotech space, which may impact Kintara's standing.
- Insider selling by a few executives has raised red flags for some investors, suggesting potential lack of confidence in the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KTRA Latest News
No recent news available for KTRA.
Leadership: Jeffrey A. Bacha
CEO
Jeffrey A. Bacha has extensive experience in the biotechnology sector, having held various leadership roles throughout his career. He has a strong background in corporate strategy and business development, with a focus on advancing innovative therapies. Bacha's educational credentials include a degree in business administration, equipping him with the skills necessary to lead Kintara Therapeutics.
Track Record: Under Jeffrey A. Bacha's leadership, Kintara has successfully transitioned its focus to innovative cancer therapies, rebranding from DelMar Pharmaceuticals to Kintara Therapeutics. He has played a pivotal role in establishing strategic partnerships, including the alliance with Guangxi Wuzhou Pharmaceutical, to enhance the company's market presence.
KTRA Healthcare Stock FAQ
What happened to Kintara Therapeutics, Inc. (KTRA) stock?
Kintara Therapeutics, Inc. (KTRA) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
Can I still buy KTRA shares?
No. KTRA stopped trading on public markets in October 2024, so the shares are not available through a broker. Anything you see quoted for KTRA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before KTRA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Kintara Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Kintara Therapeutics, Inc. do?
Kintara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative anti-cancer therapies. The company’s primary products, VAL-083 and REM-001, are designed to treat drug-resistant solid tumors and cutaneous metastatic breast cancer, respectively. Kintara is advancing these compounds through clinical trials to address significant unmet medical needs in oncology.
How does Kintara Therapeutics, Inc. navigate regulatory approval processes?
Kintara Therapeutics, Inc. follows a structured approach to navigate regulatory approval processes, focusing on compliance with FDA guidelines and protocols for clinical trials. The company aims to secure necessary approvals for its lead compounds, VAL-083 and REM-001, by conducting rigorous Phase III trials to demonstrate safety and efficacy. Successful trial outcomes will be critical for Kintara to submit applications for market authorization.
What are the main risks for KTRA?
Kintara Therapeutics, Inc. faces several risks, including the dependence on successful clinical trial results, which are crucial for future funding and growth. Additionally, the company must navigate regulatory hurdles that could delay product approvals and market entry. The competitive landscape in the oncology sector poses a threat, as established players may overshadow Kintara's efforts to gain market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company profile and financial information. Limited employee count may affect operational insights.